Tags

Type your tag names separated by a space and hit enter

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Int J Geriatr Psychiatry. 2009 May; 24(5):532-8.IJ

Abstract

OBJECTIVES

The post-hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS-cog single-items or SIB subscales for patients with moderate to severe AD.

METHODS

Data from six multicentre, randomised, placebo-controlled, parallel-group, double-blind, 6-month studies were used as the basis for these post-hoc analyses. All patients with a Mini-Mental State Examination (MMSE) score of less than 20 were included. Analyses of patients with moderate AD (MMSE: 10-19), evaluated with the Alzheimer's disease Assessment Scale (ADAS-cog) and analyses of patients with moderate to severe AD (MMSE: 3-14), evaluated using the Severe Impairment Battery (SIB), were performed separately.

RESULTS

The mean change from baseline showed a significant benefit of memantine treatment on both the ADAS-cog (p < 0.01) and the SIB (p < 0.001) total score at study end. The ADAS-cog single-item analyses showed significant benefits of memantine treatment, compared to placebo, for mean change from baseline for commands (p < 0.001), ideational praxis (p < 0.05), orientation (p < 0.01), comprehension (p < 0.05), and remembering test instructions (p < 0.05) for observed cases (OC). The SIB subscale analyses showed significant benefits of memantine, compared to placebo, for mean change from baseline for language (p < 0.05), memory (p < 0.05), orientation (p < 0.01), praxis (p < 0.001), and visuospatial ability (p < 0.01) for OC.

CONCLUSION

Memantine shows significant benefits on overall cognitive abilities as well as on specific key cognitive domains for patients with moderate to severe AD.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Mecocci P
Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy. mecocci@unipg.it
Bladström A
No affiliation info available
Stender K
No affiliation info available

MeSH

Activities of Daily LivingAgedAlzheimer DiseaseCognitionData Interpretation, StatisticalDisease ProgressionDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleHumansLanguage DisordersMaleMemantineMemoryMulticenter Studies as TopicNeuropsychological TestsPlacebosRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment Outcome

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19274640

Citation

Mecocci, Patrizia, et al. "Effects of Memantine On Cognition in Patients With Moderate to Severe Alzheimer's Disease: Post-hoc Analyses of ADAS-cog and SIB Total and Single-item Scores From Six Randomized, Double-blind, Placebo-controlled Studies." International Journal of Geriatric Psychiatry, vol. 24, no. 5, 2009, pp. 532-8.
Mecocci P, Bladström A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry. 2009;24(5):532-8.
Mecocci, P., Bladström, A., & Stender, K. (2009). Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. International Journal of Geriatric Psychiatry, 24(5), 532-8. https://doi.org/10.1002/gps.2226
Mecocci P, Bladström A, Stender K. Effects of Memantine On Cognition in Patients With Moderate to Severe Alzheimer's Disease: Post-hoc Analyses of ADAS-cog and SIB Total and Single-item Scores From Six Randomized, Double-blind, Placebo-controlled Studies. Int J Geriatr Psychiatry. 2009;24(5):532-8. PubMed PMID: 19274640.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. AU - Mecocci,Patrizia, AU - Bladström,Anna, AU - Stender,Karina, PY - 2009/3/11/entrez PY - 2009/3/11/pubmed PY - 2010/5/27/medline SP - 532 EP - 8 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 24 IS - 5 N2 - OBJECTIVES: The post-hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS-cog single-items or SIB subscales for patients with moderate to severe AD. METHODS: Data from six multicentre, randomised, placebo-controlled, parallel-group, double-blind, 6-month studies were used as the basis for these post-hoc analyses. All patients with a Mini-Mental State Examination (MMSE) score of less than 20 were included. Analyses of patients with moderate AD (MMSE: 10-19), evaluated with the Alzheimer's disease Assessment Scale (ADAS-cog) and analyses of patients with moderate to severe AD (MMSE: 3-14), evaluated using the Severe Impairment Battery (SIB), were performed separately. RESULTS: The mean change from baseline showed a significant benefit of memantine treatment on both the ADAS-cog (p < 0.01) and the SIB (p < 0.001) total score at study end. The ADAS-cog single-item analyses showed significant benefits of memantine treatment, compared to placebo, for mean change from baseline for commands (p < 0.001), ideational praxis (p < 0.05), orientation (p < 0.01), comprehension (p < 0.05), and remembering test instructions (p < 0.05) for observed cases (OC). The SIB subscale analyses showed significant benefits of memantine, compared to placebo, for mean change from baseline for language (p < 0.05), memory (p < 0.05), orientation (p < 0.01), praxis (p < 0.001), and visuospatial ability (p < 0.01) for OC. CONCLUSION: Memantine shows significant benefits on overall cognitive abilities as well as on specific key cognitive domains for patients with moderate to severe AD. SN - 1099-1166 UR - https://www.unboundmedicine.com/medline/citation/19274640/Effects_of_memantine_on_cognition_in_patients_with_moderate_to_severe_Alzheimer's_disease:_post_hoc_analyses_of_ADAS_cog_and_SIB_total_and_single_item_scores_from_six_randomized_double_blind_placebo_controlled_studies_ DB - PRIME DP - Unbound Medicine ER -